Glinoer D, De Nayer P, Delange F, Lemone M, Toppet V, Spehl M, Grün J P, Kinthaert J, Lejeune B
Department of Endocrinology, Hôpital Saint-Pierre, Université Libre de Bruxelles, Brussels.
J Clin Endocrinol Metab. 1995 Jan;80(1):258-69. doi: 10.1210/jcem.80.1.7829623.
One hundred and eighty euthyroid pregnant women were selected at the end of the first trimester of gestation on the basis of biochemical criteria of excessive thyroid stimulation, defined as supranormal serum thyroglobulin (TG > 20 micrograms/L) associated with a low normal free T4 index (< 1.23) and/or an increased T3/T4 ratio (> 25 x 10(-3)). Women were randomized in a double blind protocol into three groups and treated until term with a placebo, 100 micrograms potassium iodide (KI)/day, or 100 micrograms iodide plus 100 micrograms L-T4/day. Parameters of thyroid function, urinary iodine excretion, and thyroid volume were monitored sequentially. Neonatal thyroid parameters, including thyroid volume by echography, were also assessed in the newborns from mothers of the three groups. In women receiving a placebo, the indices of excessive thyroid stimulation worsened as gestation progressed, with low free T4 levels, markedly increased serum TG and T3/T4 ratio. Serum TSH doubled, on the average, and was supranormal in 20% of the cases at term. Urinary iodine excretion levels were low, around 30 micrograms/L at term. The thyroid volume increased, on the average, by 30%, and 16% of the women developed a goiter, confirming the goitrogenic stimulus associated with pregnancy. Moreover, the newborns of these mothers had significantly larger thyroid volumes at birth as well as elevated serum TG levels. In both groups of women receiving an active treatment, the alterations in thyroid function associated with pregnancy were markedly improved. The increase in serum TSH was almost suppressed, serum TG decreased significantly, and changes in thyroid volume were minimized (group receiving KI) or almost suppressed (group receiving KI combined with L-T4). Moreover, in the newborns of the mothers in the two groups receiving an active treatment, serum TG was significantly lower, and thyroid volume at birth was normal. The effects of therapy were clearly more rapid and more marked in the group receiving a combination of T4 and KI than in the women receiving KI alone. The differences could be partly attributed to the slightly higher amount of iodine received by women in the combined treatment. However, the main benefits of the combined treatment were almost certainly attributable to the hormonal effects of the addition of L-T4. Furthermore, the study demonstrated that the administration of T4 did not hamper the beneficial effect of iodine supplementation. In conclusion, the present work emphasizes the potential risk of goitrogenic stimulation in both mother and newborn in the presence of mild iodine deficiency.(ABSTRACT TRUNCATED AT 400 WORDS)
根据甲状腺刺激过度的生化标准,在妊娠早期结束时选取了180名甲状腺功能正常的孕妇,甲状腺刺激过度定义为血清甲状腺球蛋白超常(TG>20微克/升),同时游离T4指数低至正常范围(<1.23)和/或T3/T4比值升高(>25×10⁻³)。将这些妇女按照双盲方案随机分为三组,用安慰剂、100微克碘化钾(KI)/天或100微克碘化物加100微克左甲状腺素(L-T4)/天治疗至足月。依次监测甲状腺功能参数、尿碘排泄和甲状腺体积。还对三组母亲所生新生儿的甲状腺参数进行了评估,包括通过超声检查测定的甲状腺体积。接受安慰剂治疗的妇女中,随着妊娠进展,甲状腺刺激过度的指标恶化,游离T4水平降低,血清TG和T3/T4比值显著升高。血清促甲状腺激素(TSH)平均翻倍,足月时20%的病例TSH高于正常水平。足月时尿碘排泄水平较低,约为30微克/升。甲状腺体积平均增加30%,16%的妇女出现甲状腺肿,证实妊娠存在致甲状腺肿刺激。此外,这些母亲所生新生儿出生时甲状腺体积显著增大,血清TG水平升高。在接受积极治疗的两组妇女中,与妊娠相关的甲状腺功能改变均得到明显改善。血清TSH升高几乎得到抑制,血清TG显著降低,甲状腺体积变化最小化(接受KI组)或几乎得到抑制(接受KI联合L-T4组)。此外,在接受积极治疗的两组母亲所生新生儿中,血清TG显著降低,出生时甲状腺体积正常。与单独接受KI治疗的妇女相比,接受T4和KI联合治疗的组治疗效果明显更快、更显著。这些差异部分可归因于联合治疗组妇女摄入的碘量略高。然而,联合治疗的主要益处几乎肯定归因于添加L-T4的激素作用。此外,该研究表明给予T4并不妨碍碘补充的有益效果。总之,本研究强调了在轻度碘缺乏情况下,母亲和新生儿均存在致甲状腺肿刺激的潜在风险。(摘要截选至400字)